Novartis Ag Adr Stock Price To Book
| NVS Stock | USD 111.56 0.66 0.59% |
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Novartis |
Novartis AG ADR Company Price To Book Analysis
Novartis' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Novartis Price To Book | 5.03 X |
Most of Novartis' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Novartis AG ADR has a Price To Book of 5.0321 times. This is 80.4% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to book for all United States stocks is 47.09% higher than that of the company.
Novartis Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in price to book category among its peers.
Novartis Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 237.76 B | ||||
| Shares Outstanding | 1.98 B | ||||
| Shares Owned By Institutions | 6.76 % | ||||
| Number Of Shares Shorted | 5.04 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 5.03 X | ||||
| Price To Sales | 4.29 X | ||||
| Revenue | 51.72 B | ||||
| Gross Profit | 38.91 B | ||||
| EBITDA | 20.71 B | ||||
| Net Income | 11.94 B | ||||
| Cash And Equivalents | 4.64 B | ||||
| Cash Per Share | 8.84 X | ||||
| Total Debt | 31.26 B | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 22.30 X | ||||
| Cash Flow From Operations | 17.62 B | ||||
| Short Ratio | 2.17 X | ||||
| Earnings Per Share | 5.87 X | ||||
| Price To Earnings To Growth | 3.34 X | ||||
| Target Price | 109.37 | ||||
| Number Of Employees | 75.88 K | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 221.64 B | ||||
| Total Asset | 102.25 B | ||||
| Retained Earnings | 49.65 B | ||||
| Working Capital | 1.01 B | ||||
| Current Asset | 22.84 B | ||||
| Current Liabilities | 23.71 B | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.53 % | ||||
| Net Asset | 102.25 B | ||||
| Last Dividend Paid | 3.86 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.